» Articles » PMID: 36192408

Increased Concentrations of Conjugated Bile Acids Are Associated with Osteoporosis in PSC Patients

Overview
Journal Sci Rep
Specialty Science
Date 2022 Oct 3
PMID 36192408
Authors
Affiliations
Soon will be listed here.
Abstract

Primary sclerosing cholangitis (PSC) is an idiopathic cholestatic liver disease characterized by chronic inflammation and progressive fibrosis of intra- and extrahepatic bile ducts. Osteoporosis is a frequent comorbidity in PSC, and we could previously demonstrate that IL17-dependent activation of bone resorption is the predominant driver of bone loss in PSC. Since we additionally observed an unexpected heterogeneity of bone mineral density in our cohort of 238 PSC patients, the present study focused on a comparative analysis of affected individuals with diagnosed osteoporosis (PSC, n = 10) or high bone mass (PSC, n = 7). The two groups were not distinguishable by various baseline characteristics, including liver fibrosis or serum parameters for hepatic function. In contrast, quantification of serum bile acid concentrations identified significant increases in the PSC group, including glycoursodeoxycholic acid (GUDCA), an exogenous bile acid administered to both patient groups. Although cell culture experiments did not support the hypothesis that an increase in circulating bile levels is a primary cause of PSC-associated osteoporosis, the remarkable differences of endogenous bile acids and GUDCA in the serum of PSC patients strongly suggest a yet unknown impairment of biliary metabolism and/or hepatic bile acid clearance in this patient subgroup, which is independent of liver fibrosis.

Citing Articles

The short-chain fatty acid receptors Gpr41/43 regulate bone mass by promoting adipogenic differentiation of mesenchymal stem cells.

Behler-Janbeck F, Baranowsky A, Yorgan T, Jaeckstein M, Worthmann A, Fuh M Front Endocrinol (Lausanne). 2024; 15:1392418.

PMID: 39363899 PMC: 11446854. DOI: 10.3389/fendo.2024.1392418.


Microbiota metabolites in bone: Shaping health and Confronting disease.

Han D, Wang W, Gong J, Ma Y, Li Y Heliyon. 2024; 10(7):e28435.

PMID: 38560225 PMC: 10979239. DOI: 10.1016/j.heliyon.2024.e28435.


Cholestyramine alleviates bone and muscle loss in irritable bowel syndrome via regulating bile acid metabolism.

Chen M, Wei W, Li Y, Ge S, Shen J, Guo J Cell Prolif. 2024; 57(8):e13638.

PMID: 38523511 PMC: 11294414. DOI: 10.1111/cpr.13638.

References
1.
Chapman R, Fevery J, Kalloo A, Nagorney D, Boberg K, Shneider B . Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010; 51(2):660-78. DOI: 10.1002/hep.23294. View

2.
. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51(2):237-67. DOI: 10.1016/j.jhep.2009.04.009. View

3.
Kummen M, Holm K, Anmarkrud J, Nygard S, Vesterhus M, Hoivik M . The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2016; 66(4):611-619. DOI: 10.1136/gutjnl-2015-310500. View

4.
Yorgan T, Peters S, Jeschke A, Benisch P, Jakob F, Amling M . The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5. J Bone Miner Res. 2015; 30(7):1175-83. DOI: 10.1002/jbmr.2461. View

5.
Li Z, Huang J, Wang F, Li W, Wu X, Zhao C . Dual Targeting of Bile Acid Receptor-1 (TGR5) and Farnesoid X Receptor (FXR) Prevents Estrogen-Dependent Bone Loss in Mice. J Bone Miner Res. 2018; 34(4):765-776. DOI: 10.1002/jbmr.3652. View